Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Next Generation Personalized Neuroblastoma Therapy
NCT02780128Phase 1Terminated
- Start
- Jul 2016
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceritinib and ribociclib in neuroblastoma (2 arms). Primary endpoints: Incidence of dose limiting toxicities at 28 days, Area under the curve at 28 days and 1 more. Started Jul 2016; status: terminated.
02
Drugs
ceritinibribociclib
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02780128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780128.